top of page

New Testosterone Therapy on the Horizon for TRT. A Novel Testosterone Peptide ACE -167.

Explore Acesis Biomed's natural testosterone breakthrough. A safer, innovative treatment awaits.

Testosterone TRT online and enclomiphene for men with low t online

In the realm of men's health, one issue looms large and with growing concern: low testosterone. This hormonal deficiency isn't a mere individual challenge; it's rapidly shaping up as a public health crisis. And while the magnitude of the problem deepens, the treatment landscape offers little solace. For nearly a century, solutions have hinged predominantly on synthetic testosterone—formulations rooted in the 1930s. Such an enduring reliance on outdated methods highlights an urgent call for groundbreaking approaches to tackle this pervasive ailment.

Understanding the Current Treatment Landscape

At the heart of the low testosterone issue lies a medical condition known as hypogonadism. Often likened to “male menopause”, this condition mirrors the hormonal shifts women face during menopause. Men grappling with hypogonadism frequently report shifts in mood, diminished energy, challenges in fertility, and even weakened bone health–all of which are symptoms that can deeply impact daily life.

But why does this decline happen? The curtain begins to fall on testosterone levels steadily after the age of 30, presenting a ticking biological clock for many men. In terms of addressing this decline, the contemporary medical toolkit primarily features synthetic testosterone and anabolic steroids, typically administered through injections, patches, or gels. However, these aren't silver bullets; along with their promise come considerable risks, including notable side effects and a concerning potential for misuse and abuse. [1] [2]

Adding a layer to this narrative, the FDA has green-lighted an oral testosterone replacement therapy (TRT) capsule by Clarus Therapeutics. While this does represent a stride in treatment avenues, it's not without its constraints. Its foundation in 70-year-old chemistry and its prescribed use predominantly for men aged 40 to 65 showcase its limitations. Younger and older men remain largely underserved, emphasizing the pressing need for more comprehensive and innovative therapeutic approaches. [3]

Acesis Biomed: Charting a New Course

Acesis Biomed, a Colorado and London-based biomedical company, is taking a different road in the realm of testosterone treatments. Instead of relying on traditional, synthetic methods, they're exploring novel ways to address the issue. Central to their efforts is ACE-167; this compound, unlike others in its class, is a non-steroidal oral peptide therapy. The idea behind it is intriguing: rather than introducing external testosterone into the body, why not encourage the body itself to produce more of it naturally?

So, how does ACE-167 aim to do this? It's a question of biology and a bit of ingenious thinking. The compound is known as a testosterone peptide modulator, a molecule designed to influence certain cellular processes. Dr. Vassilios Papadopoulous, a key figure in this research, has provided valuable insights into its function. The science boils down to this: for our bodies to produce steroids like testosterone, cholesterol needs to reach a specific part of our cells called the mitochondrial membrane. There's a set of proteins that manage this transportation. ACE-167's role is to fine-tune this process, making it more efficient and thus potentially leading to increased natural testosterone production. [4]

Distinguishing ACE-167 from Current Treatments

If we take a closer look at today's testosterone treatments, we see that many of them, like the usual TRTs, come with their own set of problems. Some of these treatments might increase the chances of serious health issues like strokes, heart attacks, and high blood pressure. There's also some worry about these treatments possibly leading to prostate problems or even making it hard for men to have children in the future because of lowered sperm counts.

Enter ACE-167, which, from its conception, promises a different journey for those seeking relief from low testosterone levels. A pivotal point made by Dr. Costas Karatzas, CEO of Acesis Biomed, is that ACE-167 is fundamentally different in its composition—it's a peptide, not a steroid. To put it in simpler terms, if traditional TRTs are like introducing a foreigner who doesn't speak the local language into a new country, ACE-167 is akin to a local guide facilitating communication and understanding. Peptides generally have a subtler, more harmonious way of interacting with our bodies compared to the often forceful and sometimes disruptive nature of steroids.

But beyond its composition, the overarching vision for ACE-167 is both thoughtful and compelling. It doesn't aim to flood the body with an external source of testosterone. Instead, its goal is to stimulate the body's innate ability to produce testosterone. This could mean a more natural, physiological response—a system in balance, producing the required testosterone without overstepping or causing unnecessary disruptions. It's akin to teaching someone to fish rather than just giving them a fish, providing a sustainable solution that aligns with the body's intrinsic rhythm. [5]

The Broader Impact of Acesis Biomed's Innovation

Over the past decade, the medical community has cast a wary eye on testosterone replacement therapies (TRTs). This unease crystallized around 2014 and 2015, when the FDA issued a black box warning on these treatments, signifying potential safety concerns. Imagine, for a moment, seeing a warning label on a familiar product; it certainly makes you think twice about its safety.

Meanwhile, another concern bubbles under the surface of the pharmaceutical industry: the impending "patent cliff." Here's what that means: Patents on many current testosterone treatments are about to run out in the next 6–8 years. When they do, we might see a sudden influx of generic versions. This change could create a mixed bag of options for patients, muddling the waters of what's truly safe and effective. [4]

Against this backdrop, Acesis Biomed is taking steps in a different direction. Their work isn't about making another version of what's already out there; they're looking at a new way to tackle the problem. The hope is to provide a solution that doesn't just follow the old path but paves a new one, focusing on safety and addressing the real needs of those with hypogonadism and related health concerns.

Interested in learning more about testosterone therapies? Every individual is unique, and what works for one might not be ideal for another. At REGENX Health, we prioritize your individual needs. Our team of experts is dedicated to providing comprehensive evaluations, guiding you through the maze of options, and helping you make informed decisions. Don't navigate this journey alone. Reach out today, and let's chart the best course for your well-being together.


bottom of page